| Assessment Status | Rapid Review complete |
| HTA ID | 22035 |
| Drug | Carglumic acid |
| Brand | Ucedane® |
| Indication | Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency. |
| Assessment Process | |
| Rapid review commissioned | 16/05/2022 |
| Rapid review completed | 21/06/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that carglumic acid (Ucedane®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
